

Registration number 723137

Shoki Medics Limited

Abridged accounts

for the year ended 31/12/2024

Shoki Medics Limited

Contents

	Page
Directors and other information	3
Statement of Directors' Responsibilities	4
Abridged balance sheet	5
Notes to the abridged financial statements including Statement of Accounting Policies	6 - 8

Shoki Medics Limited

Directors and other information

Directors	Shaharyar Abdullah Basra Shaharyar
Secretary	Basra Shaharyar
Company number	723137
Registered office	Apartment 118 Meridian Court Ashtown Dublin 15
Taxation Agents	John P. Feeney Cregg Co. Sligo
Bankers	Allied Irish Bank 93A Cabra Road Dublin 7.

Shoki Medics Limited

Statement of Directors' responsibilities and declaration on unaudited financial statements

The directors made the following statement in respect of the unaudited financial statements:

General Responsibilities

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable Irish law and Generally Accepted Accounting Practice in Ireland including the accounting standards issued by the Accounting Standards Board and published by the Auditing Practices Board in the UK and Ireland.

Irish company law requires the directors to prepare financial statements for each financial period which give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

The directors confirm that they have complied with the above requirements in preparing the financial statements.

The directors are responsible for keeping proper books of account which disclose with reasonable accuracy at any time the financial position of the company and to enable them to ensure the financial statements are prepared in accordance with accounting standards generally accepted in Ireland and with Irish statute comprising the Companies Acts 1963 to 2014 and all Regulations to be construed as one with those Acts. They are responsible for ensuring that the company otherwise complies with the provisions of those Acts relating to financial statements in so far as they are applicable to the company.

They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Where financial statements are to be published on the web, the directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website.

Directors' declaration on unaudited financial statements

In relation to the financial statements as set out on pages 5 to 7:

- The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have prepared on the going concern basis on the grounds that the company will continue in business.
- The directors confirm that they have made available all the company's accounting records and provided all the information necessary for the compilation of the financial statements.
- The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the year ended 31 December 2024.

On behalf of the board

Shaharyar Abdullah
Director

Basra Shaharyar
Director

Date: - 11th August 2025.

Shoki Medics Limited

**Abridged balance sheet
as at 31/12/24**

	Notes	2025		2024	
		€	€	€	€
Fixed assets					
Tangible assets	4		1,047		1,396
Current assets					
Stocks		-		-	
Debtors		-		-	
Cash at bank and in hand		<u>29,231</u>		<u>4,520</u>	
		29,231		4,520	
Creditors: amounts falling due within one year	5	<u>(16,603)</u>		<u>(4,628)</u>	
Net current assets / (liabilities)			<u>12,628</u>		<u>(108)</u>
Net assets			<u>13,675</u>		<u>1,288</u>
Capital and reserves					
Called up share capital	3		100		100
Profit and loss account			<u>13,575</u>		<u>1,188</u>
Equity shareholders' funds			<u>13,675</u>		<u>1,288</u>

We, as Directors of Shoki Medics Limited, state that:

(A) The company is availing itself of the exemptions provided for by Chapter 15 of Part 6 of the Companies Act 2014.

(B) The company is availing itself of the exemption provided on the grounds that it complies with the conditions specified in section 358 are satisfied.

(C) The shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2) of the Companies Act 2014.

(D) We acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare Financial Statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a year and to comply with the provisions of the Companies Act 2014 relating to Financial Statements so far as they are applicable to the company.

(E) The company has relied on the specified exemption contained in section 352. We have done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged Financial Statements have been properly prepared in accordance with section 353.

On behalf of the board

Shaharyar Abdullah
Director

Basra Shaharyar
Director

The notes on pages 6 – 7 form an integral part of these financial statements.

Shoki Medics Limited

Notes to the abridged financial statements for the year ended 31/12/2024

..... continued

1. Statement of accounting policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

1.1. Basis of preparation

The accounts have been prepared in accordance with accounting standards generally accepted in Ireland and Irish statute comprising the Companies Acts 1963 to 2014, Accounting Standards generally accepted in Ireland in preparing financial statements giving a true and fair view are those issued by the Accounting Standards Board and published by the Auditing Practices Board in the UK and Ireland.

1.2. Cash flow statement

The company meets the size criteria for a small company set by the Companies (Amendment) Act, 1986 and therefore, in accordance with FRS1: Cash flow statements, it has not prepared a cash flow statement.

1.3. Turnover Policy

Turnover represents the total invoice value of sales made during the period.

1.4. Tangible fixed assets and depreciation

Depreciation

Depreciation is provided on all tangible fixed assets, at rates calculated to write off the cost less residual value, of each asset systematically over its expected useful life, as follows:

Office Equipment - 20% Straight Line

2. Directors and their interests

The directors who served during the year and their interests in the company are as stated below:

	Ordinary shares	
	31/12/24	31/12/2023
Shaharyar Abdullah	50	50
Basra Shaharyar	50	50

There were no changes in shareholdings between 01/01/25 and the date of signing the financial statements.

3. Share capital

	2024	2023
	€	€
Authorised equity		
100,000 Ordinary shares of €1 each	<u>100,000</u>	<u>100,000</u>
Allotted, called up and fully paid equity		
100 Ordinary shares of €1 each	<u>100</u>	<u>100</u>

Shoki Medics Limited

**Notes to the abridged financial statements
for the year ended 31/12/2024**

..... continued

		Tangible fixed assets €
4. Fixed assets		
Cost		
At 01/01/24		-
Additions		1,745
Disposals		=
At 31/12/24		<u>1,745</u>
Depreciation		
At 01/01/24		349
On disposals		-
Charge for period		<u>349</u>
At 31/12/24		<u>698</u>
Net book values		
At 31/12/24		<u>1,047</u>
At 31/12/23		<u>1,396</u>
5. Creditors: amounts falling due within one year	2024	2023
	€	€
<i>Other creditors</i>		
Directors' accounts	2,154	780
Accruals and deferred income	1,000	770
<i>Taxation creditors</i>		
Corporation tax	1,788	217
VAT	6,546	-
PAYE/PRSI	<u>5,115</u>	<u>2,861</u>
	<u>16,603</u>	<u>4,628</u>
6. Accounting Periods		
The current accounts are for a period of 1 year		
The comparative accounts are for a period of 17 months and 1 week.		

7. Approval of financial statements

The financial statements were approved by the Board on 11th August 2025 and signed on its behalf by:

Shaharyar Abdullah
Director

Basra Shaharyar
Director